GLP-1 Therapies, Gut Microbiome, and Liver Disease in Type 2 Diabetes Review

Metabolic dysfunction-associated steatotic liver disease (MASLD), including its more severe form MASH (Metabolic dysfunction-associated steatohepatitis), is a significant comorbidity affecting more than 60% of patients with Type 2 Diabetes Mellitus (T2DM). The gut microbiome plays a crucial role in the development and progression of MASLD through the gut-liver axis. Despite the known benefits of GLP-1-based therapies for T2DM and obesity, the specific mechanisms by which these drugs modulate the gut microbiome to improve MASLD/MASH outcomes remain an active area of investigation.

The review highlighted compelling evidence from preclinical models demonstrating the multifaceted benefits of GLP-1 RAs. For instance, liraglutide treatment in preclinical models led to the normalization of the Firmicutes/Bacteroidetes ratio and significantly increased the abundance of beneficial bacteria like Bifidobacterium and Lactobacillus species. Similarly, tirzepatide, a dual GLP-1/GIP receptor agonist, was shown to significantly reduce hepatic steatosis (fatty liver) and increase Akkermansia abundance in diabetic mice. Semaglutide, another potent GLP-1 RA, was found to improve gut barrier integrity, which is critical in preventing bacterial translocation and reducing liver inflammation. The most significant finding is the consistent evidence that GLP-1-based therapies not only improve metabolic parameters but also profoundly modulate the gut microbiome composition and function, leading to direct benefits in MASLD/MASH pathology.